R&D at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mineralys Therapeutics, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mineralys Therapeutics, Inc.'s R&D?
- Mineralys Therapeutics, Inc. (MLYS) reported R&D of $24.37M in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s R&D changed year-over-year?
- Mineralys Therapeutics, Inc.'s R&D decreased by 35.7% year-over-year, from $37.88M to $24.37M.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s R&D?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s R&D has grown at a 71.3% compound annual growth rate (CAGR), from $26.25M to $132.01M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.